Why the study?
Is long-term monitoring of SvO2 by an implanted right ventricular sensor feasible and stable in patients with heart failure?
Is long-term monitoring of SvO2 by an implanted right ventricular sensor feasible and stable in patients with heart failure?
Long-term monitoring of mixed venous oxygen saturation (SvO2) via an implanted right ventricular sensor appears feasible and stable over 6 years in patients with heart failure.
Supports feasibility of long-term SvO2 sensor monitoring in HF; leaves open prospective validation before clinical adoption.
INTRODUCTION: Mixed venous oxygen saturation (SvO(2)) is a standard invasive measure used in the management of congestive heart failure patients. The reliability of a long-term SvO(2) sensor remains unproven. METHODS: Nine patients (NYHA Class I/II, n=2/7) were implanted with a dual chamber pacemaker modified to utilize a right ventricular SvO(2) lead (Medtronic Inc., Models 8007/4327A IPG/Lead). Invasive studies compared sensor SvO(2) to reference (Optical Swan-Ganz catheter) at 0, 3 and 9 months. Symptom limited tests (Bike(max)) with metabolic assessment and arterial oxygen saturation measurements performed 1-7 days, 3.5 and 9.5 months post-implant allowed for cardiac output calculations. Long-term sensor performance was confirmed by submaximal tests, Bike(subm) in years 1-3, and Walk(in-place) every 6 months for the duration of follow-up. RESULTS: Sensor SvO(2) readings were stable over time when compared to the Swan-Ganz Catheter. Non-invasive CO measured during Bike(max) was in normal ranges for this patient population, 3.7+/-0.9 l/min at rest and 8.4+/-2.2 l/min at peak-exercise. Resting SvO(2) values from Bike(subm) and Walk(in-place) did not change significantly over time (P>0.1 vs. 1 year) and neither did the change from rest to peak exercise during Bike(subm) (P>0.05 vs. 1 year) or Walk(in-place) (P>0.05 vs. 4 year). CONCLUSION: While limited in size, this small pilot study suggests that long-term monitoring of SvO(2) by implanted devices may be feasible. The clinical value remains to be proven in future studies.
No takes yet. Share an insight, caveat, or question.
Kjellström et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: